Precision Medicine PowerPoint Presentation

Precision Medicine PowerPoint Presentation

2017-12-08 94K 94 0 0


From Promise to Practice. PRECISION ONCOLOGY IS THE FUTURE OF CANCER CARE.. Tumor genome data informs cancer treatment and clinical pathways, resulting in better health outcomes.. New cancer therapies target the molecular pathways that lead to tumor genesis and progression.. ID: 613599

Embed code:

Download this presentation

DownloadNote - The PPT/PDF document "Precision Medicine" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentations text content in Precision Medicine


Precision Medicine

From Promise to Practice



Tumor genome data informs cancer treatment and clinical pathways, resulting in better health outcomes.

New cancer therapies target the molecular pathways that lead to tumor genesis and progression.

Most cancers harbor mutations leading to disrupted biological pathways and tumor initiation.


New Approaches: Precision Medicine and Immunotherapy

Recent investments in biomedical research have led to major advances in precision medicine and immunotherapy. In 2016, the Food and Drug Administration approved:16 new and expanded use cancer therapies1First liquid biopsy diagnostic test for lung cancer mutations 2First next-generation sequencing diagnostic test to identify patients with advanced ovarian cancer eligible for a particular cancer treatment3


US Food and Drug Administration: Hematology/oncology (cancer) approvals & safety notifications.


US Food and Drug Administration: cobas EGFR Mutation Test v2.

3 US

Food and Drug Administration: Rucaparib. InformationOnDrugs/ApprovedDrugs/ucm533891.htm


Precision Cancer Treatment – a new Paradigm


A Three Year Trend

In 2016, for the third year in a row, personalized medicines accounted for more than 20 percent of all new molecular entities (NMEs) approved

by the Us Food and Drug Administration (FDA).

A New Molecular Entity (NME) or New Chemical Entity (NCE) is a drug or chemical that is without precedent among regulated and approved drug products. The NME designation indicates that a drug in development is not a version or derivative of an existing and previously investigated, trialed and approved substance. Being labeled as entirely 'new' or first-in-class molecule dictates that certain types of clinical trials must be run, and that particular attention must be paid to proving a drugs safety.


Newly Approved Medicines

The six personalized medicines approved in 2016 include: Rubraca (rucaparib) for the treatment of advanced ovarian cancer. The decision to use this product is informed by the BRCA1/2 biomarker status in patients.Exondys 51 (eteplirsen) for the treatment of Duchenne muscular dystrophy. The decision to use this product is informed by the DMD mutation biomarker status in patients.Epclusa (sofosbuvir and velpatasvir) for the treatment of chronic hepatitis C infection. The decision to use this product is informed by the HCV genotype status of the viral infection in patients.Tecentriq (atezolizumab) for the treatment of advanced or metastatic urothelial cancer and metastatic non-small cell lung cancer. The decision to use this product is informed by PD-L1 expression levels in the tumors of patients.Venclexta (venetoclax) for the treatment of chronic lymphocytic leukemia. The decision to use this product is informed by the chromosome 17p deletion biomarker status in patients.Zepatier (elbasvir and grazoprevir) for the treatment of chronic hepatitis C infection. The decision to use this product is informed by the HCV genotype 1 and 4 biomarker status of the viral infection in patients.

Personalized Medicine in Oncology

Nowhere is the transformation of healthcare toward personalized medicine more clear that in oncology. Of the six personalized NMEs approved in 2016,

three are oncology drugs.


Newly Approved Indications

FDA also approved several significant new personalized medicine indications for previously approved drugs in 2016. These approvals redefine the drugs’ intended populations and provide patients with effective personalized treatment options.


list of new personalized medicines in 2016 should therefore be complemented with reference to newly approved indications








(pembrolizumab) and


(atezolizumab) for new molecularly defined subsets of patients.


Pharmacogenomic Biomarkers in Drub Labeling

Source: Information last updated 03/14/2017

Total number of FDA - approved drugs with biomarker information provided on their drug label*

201716561 / 165 classifiedOncology/Hematology


pharmacogenomics biomarkers

are included on FDA-approved drug label*


The FDA has approved targeted therapies for the treatment of some patients with the following types of cancer – “on label”:Adenocarcinoma of the stomach or gastroesophageal junction: Trastuzumab (Herceptin®), ramucirumab (Cyramza®) Bladder cancer: Atezolizumab (Tecentriq™), nivolumab (Opdivo®)Brain cancer: Bevacizumab (Avastin®), everolimus (Afinitor®)Breast cancer: Everolimus (Afinitor®), tamoxifen (Nolvadex), toremifene (Fareston®), Trastuzumab (Herceptin®), fulvestrant (Faslodex®), anastrozole (Arimidex®), exemestane (Aromasin®), lapatinib (Tykerb®), letrozole (Femara®), pertuzumab (Perjeta®), ado-trastuzumab emtansine (Kadcyla®), palbociclib (Ibrance®), ribociclib (Kisqali®)Cervical cancer: Bevacizumab (Avastin®)Colorectal cancer: Cetuximab (Erbitux®), panitumumab (Vectibix®), bevacizumab (Avastin®), ziv-aflibercept (Zaltrap®), regorafenib (Stivarga®), ramucirumab (Cyramza®)Dermatofibrosarcoma protuberans: Imatinib mesylate (Gleevec®)Endocrine/neuroendocrine tumors: Lanreotide acetate (Somatuline® Depot), avelumab (Bavencio®)Head and neck cancer: Cetuximab (Erbitux®), pembrolizumab (Keytruda®), nivolumab (Opdivo®) Gastrointestinal stromal tumor: Imatinib mesylate (Gleevec®), sunitinib (Sutent®), regorafenib (Stivarga®)Giant cell tumor of the bone: Denosumab (Xgeva®)Kidney cancer: Bevacizumab (Avastin®), sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), temsirolimus (Torisel®), everolimus (Afinitor®), axitinib (Inlyta®), nivolumab (Opdivo®), cabozantinib (Cabometyx™), lenvatinib mesylate (Lenvima®)Leukemia: Tretinoin (Vesanoid®), imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Bosulif®), rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), ibrutinib (Imbruvica®), idelalisib (Zydelig®), blinatumomab (Blincyto®), venetoclax (Venclexta™), ponatinib hydrochloride (Iclusig®) Liver cancer: Sorafenib (Nexavar®)Lung cancer: Bevacizumab (Avastin®), crizotinib (Xalkori®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib dimaleate (Gilotrif®), ceritinib (LDK378/Zykadia™), ramucirumab (Cyramza®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), osimertinib (Tagrisso™), necitumumab (Portrazza™), alectinib (Alecensa®), atezolizumab (Tecentriq™)Lymphoma: Ibritumomab tiuxetan (Zevalin®), denileukin diftitox (Ontak®), brentuximab vedotin (Adcetris®), rituximab (Rituxan®), vorinostat (Zolinza®), romidepsin (Istodax®), bexarotene (Targretin®), bortezomib (Velcade®), pralatrexate (Folotyn®), ibrutinib (Imbruvica®), siltuximab (Sylvant®), idelalisib (Zydelig®), belinostat (Beleodaq®), obinutuzumab (Gazyva®), nivolumab (Opdivo®), pembrolizumab (Keytruda®)Multiple myeloma: Bortezomib (Velcade®), carfilzomib (Kyprolis®), panobinostat (Farydak®), daratumumab (Darzalex™), ixazomib citrate (Ninlaro®), elotuzumab (Empliciti™) Myelodysplastic/myeloproliferative disorders: Imatinib mesylate (Gleevec®), ruxolitinib phosphate (Jakafi®)Neuroblastoma: Dinutuximab (Unituxin™)Ovarian epithelial/fallopian tube/primary peritoneal cancers: Bevacizumab (Avastin®), olaparib (Lynparza™), rucaparib camsylate (Rubraca™), niraparib tosylate monohydrate (Zejula™)Pancreatic cancer: Erlotinib (Tarceva®), everolimus (Afinitor®), sunitinib (Sutent®)Prostate cancer: Cabazitaxel (Jevtana®), enzalutamide (Xtandi®), abiraterone acetate (Zytiga®), radium 223 dichloride (Xofigo®)Skin cancer: Vismodegib (Erivedge®), sonidegib (Odomzo®), ipilimumab (Yervoy®), vemurafenib (Zelboraf®), trametinib (Mekinist®), dabrafenib (Tafinlar®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), cobimetinib (Cotellic™), alitretinoin (Panretin®), avelumab (Bavencio®)Soft tissue sarcoma: Pazopanib (Votrient®), olaratumab (Lartruvo™), alitretinoin (Panretin®)Systemic mastocytosis: Imatinib mesylate (Gleevec®)Thyroid cancer: Cabozantinib (Cometriq®), vandetanib (Caprelsa®), sorafenib (Nexavar®), lenvatinib mesylate (Lenvima®) 




Drug Development – Biopharmaceutical Companies ARE committed

Personalized medicine is rapidly coming of age. Drug development pipelines are full of new targeted therapies that offer the hope of effective new treatment options for patients.

Biopharmaceutical companies nearly doubled their R&D investment in personalized medicines over the past five years and expect to increase their investment by an additional 1/3 in the next five years.Biopharmaceutical researchers also predict a 69% increase in the number of personalized medicines in development over the next five years.

Source: Tufts Center for the Study of Drug Development, “Personalized Medicine Gains Traction but Still Faces Multiple Challenges,”

Impact Report

, May/June 2015, Volume 17, Number 3


Genetic/Genomic Diagnostics

Source: Concert Genetics – formerly NextGxDx – The current landscape of genetic testing - 2016

More than 5,500 new Genetic/Genomic Testing products came to market between April 2015 and September 2016.*


Coverage and Payment Policy

Coverage and Payment policies in both the public and private sectors play a critically important role in ensuring patient access and encouraging continued innovation.Healthcare policy leaders have contended that in order “to stimulate the development of a more robust diagnostics pipeline and to harness the benefits of personalized medicine in patient-centered care delivery, policymakers must create an environment that encourages increased investment in diagnostics, enables new advances in patient care that are safe, accurate and reliable, and establishes a viable pathway toward patient access.”*


Abernethy, A, Abrahams, E, Barker, A, et al. Turning the tide against cancer through sustained medical innovation: The pathway to progress.

Clinical Cancer Research.

2014;20(5): 1081-1086.


Coverage and Payment Policy

Evidence Requirements


insurance coverage of diagnostic tests, for example, will likely require practice-based evidence demonstrating value


Obtaining the real-world data necessary for generating this evidence is difficult unless the products and services are covered by payers.

Value Assessment Frameworks


for supporting health care decision-making by quantifying the value of


Many of the frameworks, however, have been criticized for failing to account for the heterogeneity of treatment


Value-Based Payment Models

CMS and private payers are also proposing new, “value-based” payment models, also known as “alternative payment models” (APMs), that seek to drive improvements in care quality and efficiency.


Clinical Integration – Operationalizing Precision Medicine

Integrating personalized medicine into health care requires



awareness and


of personalized medicine concepts amongst the public and health care workforce;


a greater emphasis on patient




the value of molecular pathways in guiding care;



infrastructure and

information management processes;


reshaping health care delivery to ensure access to personalized medicine technologies and services.


successfully integrate personalized medicine into health care, providers will need to implement a range of programs and processes


each of these areas.


2016 – meaningful progress

Despite ongoing challenges in the areas of scientific discovery, diagnostic regulatory policy, reimbursement and integration of new technologies into clinical practice,

the commitment witnessed in 2016 anticipates

a shift away from one-size-fits-all, trial-and-error medicine and toward a health care system that utilizes molecular information to improve outcomes and make the health care system more efficient.



Real-World Success

Better outcomes

Lower costsChange in Physician Decision-makingMore drug reimbursedWorkflow efficiencies

23 PFS weeks on precision medicine vs 12 PFS weeks on standard of care1$4,665 per PFS-week per patient on precision oncology vs. $5,000 on standard of care164% of patients had their care management changed182% of targeted therapy orders successfully obtained through insurance approval or clinical trials24-fold increase in molecular tumor board throughput

1. Haslem, Derrick S., et al. "A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs." Journal of Oncology Practice (2016): JOPR011486.

2. Nadauld, Lincoln, et al. "Implementation of a precision cancer program in an integrated health care system."

ASCO Annual Meeting Proceedings

. Vol. 33. No. 15_suppl. 2015.


About DocSlides
DocSlides allows users to easily upload and share presentations, PDF documents, and images.Share your documents with the world , watch,share and upload any time you want. How can you benefit from using DocSlides? DocSlides consists documents from individuals and organizations on topics ranging from technology and business to travel, health, and education. Find and search for what interests you, and learn from people and more. You can also download DocSlides to read or reference later.